REPL · Replimune Group, Inc.
$11.00
+0.49 (+4.66%)
At close · Jul 21
Going-concern doubt
— flagged Jun 29, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Jun 29, 2026
Market Cap
$923.40M
Shares
83.95M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$313.9M
-26.9%
FY2026
Diluted EPS
-$3.38
-10.1%
FY2026
Operating Cash Flow
-$280.34M
-45.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $221.18M | $189.45M | $174.96M | $126.53M | $79.55M | $56.75M | $38.76M | $22.17M | $13.52M | $6.94M | |
| $102.02M | — | $72.18M | $59.81M | $50.55M | $38.77M | $23.2M | $17.44M | $8.77M | $5.71M | $2.71M | |
| — | $98.74M | $72.18M | — | — | — | — | — | — | — | — | |
| — | $3.33M | $3.5M | $2.66M | $2.45M | $2.15M | $1.71M | $533K | $148K | $109K | $122K | |
| — | $319.92M | $261.63M | $234.77M | $177.08M | $118.31M | $79.96M | $56.2M | $30.95M | $19.23M | $9.65M | |
| — | -$319.92M | -$261.63M | -$234.77M | -$177.08M | -$118.31M | -$79.96M | -$56.2M | -$30.95M | -$19.23M | -$9.65M | |
| — | $5.43M | $14.8M | $19.39M | $3.08M | $278K | -$915K | $3.57M | $112K | -$473K | $1.94M | |
| — | -$314.49M | -$246.83M | -$215.39M | -$174M | -$118.04M | -$80.87M | -$52.63M | -$30.83M | -$19.7M | -$7.7M | |
| — | -$551K | $468K | $408K | $288K | $0 | $0 | $0 | $0 | $0 | $0 | |
| — | -$313.9M | -$247.3M | -$215.8M | -$174.28M | -$118.04M | -$80.87M | -$52.63M | -$30.83M | -$19.7M | -$7.7M | |
| — | -$313.94M | -$247.3M | -$215.79M | -$174.28M | -$118.04M | -$80.87M | -$52.63M | -$30.83M | -$19.7M | -$7.7M | |
| — | -$313.99M | -$246.7M | -$216.67M | -$167.58M | -$118.62M | -$80.28M | -$52.55M | -$31.65M | -$17.39M | -$9.14M | |
| USD/shares | — | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 | -$1.75 | — | — | — | — |
| USD/shares | — | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 | -$1.75 | — | — | — | — |
| shares | — | 92.8M | 80.56M | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.2M | 4.98M | 4.97M |
| shares | — | 92.8M | 80.56M | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.2M | 4.98M | 4.97M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Reportable Segment | -$319,919,000 | -$261,627,000 | -$234,773,000 |
Key facts
CIK
1737953
CUSIP
76029N106
13F (30d)
18 filings
18 filers
Visit website
Investor relations